Dosing Regimens News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Steven W. Pipe, MD, explores the latest developments in hemophilia A treatments and prophylactic therapies, including extended half-life agents and a groundbreaking bispecific antibody.

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support...

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Analysis of 72 patients treated in STK-001 clinical trials suggests that higher...

– New data include 24-month results from the largest and longest prospective natural history study of children and adolescents with Dravet syndrome, which showed a lack of improvement despite...

New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.